Hormone Therapy in Postprostatectomy Men With Prostate Cancer on RT

In a late-breaking abstract featured at the ESMO Congress 2022, researchers reported that preliminary analysis of aggregated data did not find evidence that hormone therapy (HT) improved overall survival (OS) compared with no HT in men undergoing radiotherapy (RT) after radical prostatectomy for localized prostate cancer.

Sarah Burdett, of the MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, presented the data.

The DADSPORT (duration of androgen suppression with postoperative radiotherapy) meta-analysis reviewed published results and additional data provided by collaborators from the NRG/RTOG 9601, GETUG-AFU 16, NRG/RTOG 0534, and RADICALS-HD trials. The impact of HT on OS and metastases-free survival (MFS) was evaluated via a fixed-effect inverse-variance analysis, stratified by HT durations of no HT, 6 months, and 24 months.

The 4 trials eligible at the time of the presentation included 4452 men with 701 deaths over a median follow-up of ? 8 years. The authors found no clear benefit in OS with HT compared with no HT (hazard ratio [HR], 0.82; 95% CI, 0.77-1.03).

Analyses of eligible subgroup data returned similar findings for 6-month (HR, 0.90; 95% CI, 0.74-1.09; P=.28; I²=0; P=.98) and 24-month HT (0.89; 95% CI, 0.72-1.10; P=.29; I²=74%; P=.05) versus no HT. However, the authors did note that evidence from 3 trials (653 events; 3364 men) suggested that 6-month HT did improve MFS compared with no HT (HR, 0.82; 95% CI, 0.70-0.96; P=.013).

“We provide the most reliable evidence to date regarding the effects of HT with postoperative radiotherapy,” the authors concluded. “Thus far, there is no clear evidence that the addition of HT improves OS, but 6-month HT improves MFS.”